With Bayer "badly broken in four places," now is not the right time to consider offloading its Consumer Health business, according to group CEO Bill Anderson. Bayer must focus its full attention for the next few years on addressing challenges which include mounting debt and costly litigation before a change to the company's structure can be considered.
Breaking up is hard to do, for Bayer at least. As it watches its biggest OTC rivals go solo, Bayer has decided to hold onto its Consumer Health business.
Join thousands of industry professionals who rely on HBW Insight for daily insights
Already a subscriber?
European Food Safety Authority finds no cause and effect relationship between Givaudan's Pacran supplement and defense against urinary tract infections.
Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.
Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.
Arkopharma's parent company Dermapharm is undertaking a strategic shift at the French firm to help it better compete in the dietary supplements market after a tough year.
European Food Safety Authority finds no cause and effect relationship between Givaudan's Pacran supplement and defense against urinary tract infections.
While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.
Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.
